1. Market Research
  2. > Pharmaceutical
  3. > Drug Development Market Trends
Escherichia coli Infections R&D Pipeline Analysis Report, Q4 2020

Escherichia coli Infections R&D Pipeline Analysis Report, Q4 2020

  • October 2020
  • 181 pages
  • ID: 5978204
  • Format: PDF
  • VPAResearch

Summary

Table of Contents

Escherichia coli Infections Pipeline Overview

The Q4 Escherichia coli Infections pipeline report is part of the VPA 110 Infectious Disease pipeline service. This quarterly review describes the pipeline of drugs under development for Escherichia coli Infections, provides an update on the mechanism of action and targets, licensing and collaboration opportunities, company profiles including their business information, and market developments.

Escherichia coli Infections Disease Types, Symptoms, Causes, and Available Treatment Options
The comprehensive report on the indication presents Escherichia coli Infections disease overview, Escherichia coli Infections types, Escherichia coli Infections symptoms, causes, and FDA/EMA approved treatment options.

Escherichia coli Infections Pipeline Trends and Insights
The year 2020 witnessed progress in innovations and the number of pipeline agents researched for Escherichia coli Infections indication. The report presents near-term and long-term pipeline development trends and potential insights.

Escherichia coli Infections Company Trends and Insights
The report analyzes the development progress, current status, investments, partnerships, and other developments of 38 companies. Business profiles and contact details of the companies actively perusing Escherichia coli Infections pipeline are assessed.

Escherichia coli Infections R&D Pipeline Development Phase Trends and Insights
From the discovery stage of development to phase 3 development, all the potential pipeline drug candidates are analyzed in the report. Escherichia coli Infections discovery stage, research stage, Phase 1, phase 2, Phase 3, IND enabling studies are provided in the research.

Small Escherichia coli Infections companies look for licensing and collaboration partners
High R&D costs and long duration pose challenges for small companies operating in the industry. Further, the presence of large companies and stringent regulations act as barriers for Escherichia coli Infections pipeline development companies. Accordingly, a significant portion of small companies presents potential licensing and collaboration opportunities.

Escherichia coli Infections Pipeline Market News and Developments during 2020
The Escherichia coli Infections industry news, pipeline research, market developments including advancement in phases, pre-clinical study results, clinical trial launches, acquisitions and mergers, regulatory approvals, and others are included in the report.

Escherichia coli Infections Mechanism of Action and Targets
Leading Mechanism of Action and targets being researched by all the companies and their progress is included. New mechanisms of actions introduced during the year, route of administration, orphan drug designation, and others are provided in the study.

New molecular entity details
Drug candidates identified as new molecular entities by FDA, EMA, and other regulators are included in the research.

Sources and Research Methodology
Data is updated daily across diseases in the infectious pipeline service. We review our quarterly pipeline reports for the latest 5 years to present longitudinal insights.

Scope and Coverage
• Escherichia coli Infections pipeline development activities across the early phase, mid-stage, and late phase pipelines including therapeutic candidates
• Drug profiles comprising of drug overview, mechanism of action, co-developers, originators, route of administration, molecule type, orphan drug status, new molecular entity, area, and other details.
• Company-company partnerships, company-institute partnerships, and investment details of companies are included
• 38 companies are included including ABAC Therapeutics SA, AstraZeneca Plc, BB100 LLC, Biomendics LLC, Bugworks Research India Pvt Ltd, ContraFect Corp, Debiopharm International SA, Eligochem Ltd, EnBiotix Inc, EveliQure Biotechnologies GmbH, F. Hoffmann-La Roche Ltd, Forge Therapeutics Inc, GlyProVac ApS, Immuron Ltd, Johnson & Johnson, Kyorin Pharmaceutical Co Ltd, Linnaeus Bioscience Inc, Meiji Seika Pharma Co Ltd, Melinta Therapeutics Inc, Merck & Co Inc, Microbiotix Inc, Navigen Inc, Neoculi Pty Ltd, Northern Antibiotics Oy, Nosopharm SAS, Ostrich Pharma USA Inc, Oxford Drug Design Ltd, Paratek Pharmaceuticals Inc, Phico Therapeutics Ltd, Procarta Biosystems Ltd, Protein Potential LLC, Pylum Biosciences Inc, Recce Pharmaceuticals Ltd, Sealife PHARMA GMBH, Soligenix Inc, Spero Therapeutics Inc, Syntiron LLC, Venus Medicine Research Center,
• Disease overview, Pipeline trends, market analysis, and other developments
• Potential licensing/new business opportunities in Escherichia coli Infections pipeline market

Highlights
• Global coverage of companies and pipeline agents
• 2020 Trends, market analysis, and developments
• Potential growth opportunities
• Comprehensive details of drug candidates

Reasons to Buy
• Drive pipeline research and commercial assessment
• Assess most promising drug candidates and stay ahead of the competition
• Strengthen your pipeline through identifying business expansion and acquisition opportunities
• Develop new candidates based on most focused targets and mechanism of actions

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

ReportLinker may already be registered as a supplier with your company. If you want to Order by PO, check with us first and we'll let you know if we are a registered supplier and what the vendor number is. Otherwise, we'll provide you with the necessary information to register ReportLinker as a vendor.

Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers

Secondary (Hypogonadotropic) Hypogonadism - Pipeline Review, H2 2020

  • $ 2000
  • November 2020
  • 72 pages

Secondary (Hypogonadotropic) Hypogonadism - Pipeline Review, H2 2020 Summary latest Pharmaceutical and Healthcare disease pipeline guide Secondary Hypogonadism - Pipeline Review, H2 2020, provides ...

  • World
  • China
  • Therapy
  • Hormone
  • Industry analysis
  • Pregnancy Rate
  • Drug Approval

ref:plp2020

Reportlinker.com © Copyright 2021. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on